•
Dec 31, 2019
Harrow Q4 2019 Earnings Report
Harrow Health reported strong gross margin and adjusted EBITDA in Q4 2019.
Key Takeaways
Harrow Health reported Q4 2019 results, highlighting strong gross margin performance and record-high adjusted EBITDA and cash flow from operations. The company does not anticipate disruptions from COVID-19 and believes it has ample supplies.
Harrow Health hit gross margin targets a year ahead of schedule in Q4 2019.
The company reported record-high adjusted EBITDA and cash flow from operations during the fourth quarter.
Harrow Health believes it has ample supplies and access to supplies for the duration of 2020 and, in most cases, into 2021.
The company is not expecting disruptions in its business or supply chain as a result of the recent COVID-19 virus concerns.